title: Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group.
abstract: A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10(6) or 10(7) TCID50 of canarypox (ALVAC) vector expressing HIV-1MN gp160 or 10(5.5) TCID50 of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 microg of HIV-1SF2 recombinant (r) gp120 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses. HIV-1MN and HIV-1SF2 neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (<65%) or rgp120 (89%) alone. ALVAC-gp160/rgp120 also elicited more frequent HIV V3-specific and fusion-inhibition antibodies, antibody-dependent cellular cytotoxicity, lymphoproliferation, and cytotoxic CD8+ T cell activity than did either vaccine alone. Trials with ALVAC expressing additional HIV components and rgp120 are underway.
authors.affiliation: Johns Hopkins University School of Public Health, Baltimore, Maryland, USA. mclement@jhsph.edu
authors.forename: M L
authors.initials: ML
authors.lastname: Clements-Mann
authors.forename: K
authors.initials: K
authors.lastname: Weinhold
authors.forename: T J
authors.initials: TJ
authors.lastname: Matthews
authors.forename: B S
authors.initials: BS
authors.lastname: Graham
authors.forename: G J
authors.initials: GJ
authors.lastname: Gorse
authors.forename: M C
authors.initials: MC
authors.lastname: Keefer
authors.forename: M J
authors.initials: MJ
authors.lastname: McElrath
authors.forename: R H
authors.initials: RH
authors.lastname: Hsieh
authors.forename: J
authors.initials: J
authors.lastname: Mestecky
authors.forename: S
authors.initials: S
authors.lastname: Zolla-Pazner
authors.forename: J
authors.initials: J
authors.lastname: Mascola
authors.forename: D
authors.initials: D
authors.lastname: Schwartz
authors.forename: R
authors.initials: R
authors.lastname: Siliciano
authors.forename: L
authors.initials: L
authors.lastname: Corey
authors.forename: P F
authors.initials: PF
authors.lastname: Wright
authors.forename: R
authors.initials: R
authors.lastname: Belshe
authors.forename: R
authors.initials: R
authors.lastname: Dolin
authors.forename: S
authors.initials: S
authors.lastname: Jackson
authors.forename: S
authors.initials: S
authors.lastname: Xu
authors.forename: P
authors.initials: P
authors.lastname: Fast
authors.forename: M C
authors.initials: MC
authors.lastname: Walker
authors.forename: D
authors.initials: D
authors.lastname: Stablein
authors.forename: J L
authors.initials: JL
authors.lastname: Excler
authors.forename: J
authors.initials: J
authors.lastname: Tartaglia
authors.forename: E
authors.initials: E
authors.lastname: Paoletti
mesh_terms: D016915:AIDS Vaccines / Q000009:adverse effects; D000328:Adult; D000917:Antibody Formation; D000920:Antibody-Dependent Cell Cytotoxicity; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis* / Q000097:blood; D015699:HIV Envelope Protein gp120 / Q000009:adverse effects / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D006801:Humans; D007115:Immunization Schedule; D007117:Immunization, Secondary; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D009500:Neutralization Tests; D011820:Rabies virus / Q000276:immunology; D013997:Time Factors; D014614:Vaccines, Synthetic / Q000009:adverse effects; D014765:Viral Vaccines / Q000009:adverse effects
chemical_list: D016915:AIDS Vaccines; C078788:ALVAC vaccine; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120; D014614:Vaccines, Synthetic; D014765:Viral Vaccines